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How I report breast magnetic resonance
imaging studies for breast cancer staging
and screening
Sarah Vinnicombe
Abstract
Magnetic resonance imaging (MRI) of the breast is the most sensitive imaging technique for the diagnosis and local
staging of primary breast cancer and yet, despite the fact that it has been in use for 20 years, there is little evidence
that its widespread uncritical adoption has had a positive impact on patient-related outcomes.
This has been attributed previously to the low specificity that might be expected with such a sensitive modality, but
with modern techniques and protocols, the specificity and positive predictive value for malignancy can exceed that of
breast ultrasound and mammography. A more likely explanation is that historically, clinicians have acted on
MRI findings and altered surgical plans without prior histological confirmation. Furthermore, modern adjuvant
therapy for breast cancer has improved so much that it has become a very tall order to show a an improvement in
outcomes such as local recurrence rates.
In order to obtain clinically useful information, it is necessary to understand the strengths and weaknesses of
the technique and the physiological processes reflected in breast MRI. An appropriate indication for the scan,
proper patient preparation and good scan technique, with rigorous quality assurance, are all essential prerequisites for
a diagnostically relevant study.
The use of recognised descriptors from a standardised lexicon is helpful, since assessment can then dictate subsequent
recommendations for management, as in the American College of Radiology BI-RADS (Breast Imaging Reporting and
Data System) lexicon (Morris et al., ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System, 2013). It
also enables audit of the service. However, perhaps the most critical factor in the generation of a meaningful
report is for the reporting radiologist to have a thorough understanding of the clinical question and of the findings
that will influence management. This has never been more important than at present, when we are in the throes of a
remarkable paradigm shift in the treatment of both early stage and locally advanced breast cancer.
Keywords: Magnetic resonance imaging, Breast cancer, Staging, BI-RADS, Screening
Background
The sensitivity of mammography for breast cancer de-
tection in women over 50 years is well over 80 % [1] and
in the symptomatic population, when combined with
breast ultrasound (US), this figure increases to around
90 %. It might then be asked why another imaging mo-
dality such as breast MRI is required at all. However, it
is well recognised that the sensitivity of mammography
is substantially lower (around 50 %) in the mammogra-
phically dense breast, even with state of the art full field
digital mammography (FFDM) [2]. Furthermore there is
limited inherent contrast in mammography; many le-
sions are indeterminate, requiring further evaluation and
biopsy; there are recognised observer limitations and it
requires radiation (albeit low dose) and breast compres-
sion, which most women find very uncomfortable.
Though many of these limitations are negated by high
quality US, this too is operator dependent, often misses
microcalcifications (the mammographic hallmark of
ductal carcinoma in situ, DCIS), and also suffers from
low specificity especially in the screening setting [3, 4].
On the other hand, dynamic contrast-enhanced breast
MRI (DCE-MRI), the ‘bread-and-butter’ MRI technique
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for breast cancer detection, has a sensitivity for invasive
cancers greater than 95 % in most series [5] and is the
most accurate imaging technique for tumour size assess-
ment in most circumstances [6, 7]. It can detect add-
itional ipsilateral foci of disease in the breast known to
harbour a cancer in up to as many as 25 % of cases [8],
and detects synchronous contralateral occult disease
with a median frequency of 4 % [9]. There are some re-
ports suggesting that it is better than mammography for
the detection of DCIS, especially more aggressive bio-
logically relevant high grade DCIS [10]. Importantly, nu-
merous studies have shown that DCE-MRI of the breast
is a far more sensitive screening modality than FFDM or
US in the detection of clinically occult breast cancer in
women at greatly increased lifetime risk, especially those
with BRCA mutations [11–14], with most studies show-
ing a doubling of the cancer detection rate with breast
MRI and little additional benefit from mammography.
So why is breast MRI not used more often in routine
practice? In countries that have resource-limited health-
care systems, such as the UK National Health Service
(NHS), timely access to MRI is a major issue, but even
in resource-rich countries such as the USA, many insur-
ance providers are refusing to reimburse breast MRI
studies except in certain well defined scenarios. Most
centres have seen an exponential increase in demand for
breast MRI, yet to date, despite numerous studies dem-
onstrating the superiority of breast MRI over conven-
tional imaging in local staging, this has not translated
into beneficial patient related outcomes. Specifically, the
evidence suggests that use of preoperative breast MRI in
patients with breast cancer results in increased mastec-
tomy rates or larger wide local excisions [15] with, at the
same time, no reduction in the incidence of positive
surgical margins (necessitating re-excision) [16, 17]
nor, ultimately, in ipsilateral in-breast local recurrence
[18]. Similarly, though there is good evidence of stage
shift as a result of the use of breast MRI for screening
of high-risk women [19], it remains to be seen whether
the increased cancer detection rate with breast MRI in
high risk women translates into improvements in
breast cancer-specific mortality [20], at least in the
BRCA 1 population.
What this seeming paradox tells us is that breast MRI
should be used judiciously; this is my own take on how
to make it as useful as possible. There should be a very
good indication for carrying out breast MRI and though
space precludes a detailed exploration of the indications
here, the situations in which I would either advocate or
consider breast MRI for local staging are listed in
Table 1. This is by no means an exhaustive list and gen-
erally, hard and fast rules are unhelpful. It is my firm
view that decisions about whether or not a breast MRI is
appropriate should be taken in the MDT meeting after
thorough discussion. For example, take a patient with a
pre-operative diagnosis of invasive lobular carcinoma
(ILC). Many centres would routinely obtain a breast MR
in any such patient and there is limited evidence from
single centre studies that it may reduce the incidence of
positive surgical margins without an increase in mastec-
tomy rates [21]. However, it is unnecessary if conven-
tional imaging has shown clearly that the disease is
multicentric and that breast conservation is not an op-
tion. Similarly, the evidence for a higher rate of syn-
chronous contralateral malignancy with ILC has been
overstated [22] and screening of the contralateral breast
is not generally indicated. On the other hand, there may
be genuine uncertainty about the local extent of disease,
yet if the patient’s comorbidities preclude surgical resec-
tion, there is no point in obtaining a breast MRI. There-
fore, choose your indication and your patient carefully!
Finally, it is incumbent on us to be aware of shifting
treatment paradigms; with increasingly sophisticated
oncoplastic surgical techniques, MR demonstration of
multifocal disease or even segmental DCIS over as much
as 6 or 7 cm need not preclude breast conservation.
Maximising the chances of obtaining a diagnostically
useful study
Once the decision to obtain a breast MRI has been
made, it is important to stack the odds in your favour. I
will not carry out a breast MR scan unless I have access
to all relevant prior imaging, whether it be conventional
mammography or MRI, and all clinical details including
timing of previous biopsies or interventions, surgery or
radiotherapy, and any histology results. All too often
clinical details state ‘right breast cancer? extent’ – this is
inadequate!
If the scan is elective, for example in the high risk
screening setting, the scan should be scheduled for
Table 1 Common Indications for Breast MRI in suspected/
known breast malignancy
Adenocarcinoma of unknown primary – suspected occult breast
malignancy
Local staging – Clinical/imaging size discrepancy
Difficulty sizing with conventional imaging – suspected multifocality
Invasive lobular carcinoma, dense breasts
Non-calcified DCIS
Potential candidate for accelerated partial breast irradiation or IORT
Response assessment (neoadjuvant chemotherapy)
Lesion characterisation/problem solving
Residual disease post wide local excision
Differential diagnosis of local recurrence and treatment effects
Screening of high risk groups (BRCA mutation carriers, previous
mantle radiotherapy)
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around day 10 of the menstrual cycle and if the patient
is on HRT it may be necessary to discontinue this for
6 weeks to minimise confounding background breast
parenchymal enhancement (BPE). In my experience this
suggestion is often not well received, but on the other
hand, this patient cohort is very highly motivated. In the
patient with known breast cancer, such scheduling is not
possible and note should be made of the date of the last
menstrual period and hormone replacement therapy
(HRT) usage.
Patient preparation is extremely important. It is im-
possible to overemphasise the role of sympathetic MR
technicians who can talk the patient through the proced-
ure and – critically - who are not afraid to manipulate
the breast in order to optimise patient positioning within
the breast coil. Cod liver oil capsules taped to the skin
can be useful to mark scars or the site of the clinical ab-
normality. The patient must lie prone without moving
for a minimum of 25 min and comfort is essential. In
my unit, the patient information sheet warns patients to
avoid a large meal prior to the scan as this can make
lying prone for the procedure very uncomfortable. The
more time spent ensuring the breasts lie centrally within
the coil, with no skin folds, the better. If the MR techni-
cians are not trained mammographers, I recommend a
trip to the breast unit to gain some experience of mam-
mography and patient positioning. Often the first scan
acquired is degraded by motion artefact, so it is a good
idea for this scan not to be the first of the dynamic series
as it may be necessary to repeat it.
Scan protocol
A detailed consideration of scan sequences and technical
developments in sequences is outwith the scope of this
article, but there are a few germane points. Though
breast MRI scans can be considered to be more or less
‘out of the box’ at 1.5T, this is not true of scans at higher
field strengths, when prior sequence optimisation on
phantoms and healthy volunteers is essential, especially
for sequences involving fat suppression (particularly dif-
fusion weighted imaging), which can be very problemat-
ical around the breast because of susceptibility effects
induced by air/soft tissue interfaces.
Unless there is good reason to believe that the patient
will only tolerate one sequence - which should be the
dynamic T1 weighted gradient echo acquisition - I com-
mence with a high resolution axial T2 weighted TSE se-
quence without fat suppression (voxel size 0.9 × 0.9 ×
2 mm). This is very valuable for evaluation of the
morphology of masses and identification of oedema,
cysts and blood products, considered in conjunction
with a non fat suppressed T1 weighted 3D gradient echo
sequence (often very useful for identification of marker
clips). I follow this with diffusion-weighted imaging
(DWI). In patients who are breast feeding or who have
other contraindications to intravenous gadolinium-based
contrast, the study can stop at this point and a surpris-
ing amount of information may be obtained, especially
in young women with prominent fibroglandular paren-
chyma [23]. However, the single most important se-
quence remains the semi-dynamic T1 weighted gradient
echo sequence, which can be 2D or 3D, with or without
fat suppression. I favour an axial 3D sequence with fat
suppression, voxel size 0.9 × 0.9 × 1.2 mm and acquisi-
tion time 45 s. True pharmacokinetic analysis is not
possible with this sequence, but it is not necessary out-
side the research arena. Nonetheless, it is important to
appreciate the effect of scan duration on enhancement
patterns; if scan time is prolonged, rapid enhancement
of a mass and washout can be missed and with a slow
injection rate, peak enhancement can be dampened
(Fig. 1). Conversely, information on kinetics should not
be acquired at the expense of spatial resolution. For this
reason I scan out to around 6 min for the dynamic series
and then obtain a high resolution T1 weighted 3D gradi-
ent echo sequence with water excitation and isotropic
resolution, voxel size 0.7 mm3, acquired in 4 minutes
30 s. This is an excellent sequence for morphology (for
example, showing non-enhancing internal septations in
fibroadenomata) and for those relatively rare malignan-
cies such as low grade classical ILC, that may enhance
relatively little and late.
How I read breast MRI studies
In my institution, the medical MR physicist and I look at
the scans together on the modality workstation and gen-
erate time-intensity curves from any regions of interest
on the subtracted dynamic series. These are subse-
quently sent to PACS for reporting. If your institution
has post-processing software this is very helpful, but I
recommend that you ascertain from the manufactures
and application specialists exactly what manipulations
have been carried out on the raw data; not all softwares
are equal and there is a dearth of literature on the repro-
ducibility of results (for example, functional tumour
volumes) between vendors. This may not matter for a
one-off diagnostic study, but it is extremely important if,
for example, one is monitoring response to neoadjuvant
chemotherapy.
My PACS hanging protocol is shown in Fig. 2. I like to
see the T2 weighted sequences, the DWI and ADC map
and the axial maximum intensity projections (MIPs)
across the top row. If it is the first MRI study, I will load
the first and second post-contrast subtracted series, the
delayed high-resolution studies and the post-processing
image captures along the bottom row. If it is a follow-up
study I will display the same sequences in top and bot-
tom rows with the older examination below.
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Fig. 2 Hanging protocol. From left to right, T2 weighted, diffusion weighted series and corresponding ADC map, MIP images (top row). On the
bottom row, from left to right, first and second subtracted series, high resolution post contrast series and post-processing
Fig. 1 The effect of acquisition time on enhancement curves. A theoretical graphical depiction of the effect of dynamic acquisition time on
apparent contrast enhancement kinetics; injection at time 0. Signal intensity (%) vs. time (minutes)
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I start by having a quick look at the MIP series to as-
certain a) whether there is any significant enhancement
in the breasts and b) how much movement there has
been during the acquisition. Secondly, I have a look at
the first and second raw and subtracted series, remem-
bering that if there has been much motion, the sub-
tracted series can be totally misleading. Artefactual
enhancement can be recognised readily by the presence
of alternating bright white and black bands and can
make sizing of a lesion difficult especially if there is sus-
pected DCIS (Fig. 3a). Here reference to the raw data
and the delayed high resolution sequence can be very
helpful (Fig. 3b). However it may be necessary to state in
the final report that confidence in accurate sizing is lim-
ited. On the other hand, significant enhancement can be
obscured and evaluation of the morphology of a mass is
challenging. Postprocessing softwares generally have an
algorithm for motion correction, but there are limits to
what can be achieved with this, especially if motion is
along the z axis.
As well as looking for the presence of significant en-
hancement I assess the degree of background parenchy-
mal enhancement (BPE) around 2 min post injection of
contrast. This is akin to assessing the amount of fibro-
glandular parenchyma on a mammogram and has the
same purpose; it should indicate the level of certainty
about whether or not a significant lesion is present. Just
as a cancer can be obscured in the dense breast on
mammography, so the presence of florid BPE can render
breast MRI interpretation difficult (Additional file 1:
Figure S4a and b). However, contrary to the situation
with mammography, there appears to be no drop in the
sensitivity with severe BPE, despite a higher rate of
examinations called abnormal [24, 25]. In the latest BI-
RADS lexicon, BPE is graded a to d for none/minimal
through to severe; the meaningless attempt to assign a
percentage figure that was present in the previous edi-
tion has, quite rightly in my view, been dropped. Care
should be taken to ensure that windowing is appropriate;
you should be able to ‘see in’ to the breast without mak-
ing window widths so great that enhancement cannot be
appreciated. Note that BPE can be asymmetrical, as
shown in Additional file 1: Figure S4c in a patient who
received unilateral whole breast adjuvant radiotherapy.
If abnormal enhancement is present, I next look at the
T2W series for a morphological correlate. This yields
useful information not only about the possible nature of
a mass, but also, in the case of known cancers, the likely
imaging phenotype. For example, Fig. 2 demonstrates
the typical MR appearances of a grade 3, hormone re-
ceptor negative cancer. The T2W scan can also enable
one to dismiss small foci of enhancement and can be
very useful to confirm, for example, that an ovoid focus
of enhancement with washout is in fact an intramam-
mary lymph node. Linking the various series together
makes this process straightforward.
If there is a T2 correlate I routinely look at the DWI
and corresponding apparent diffusion coefficient (ADC)
map. I use b values of 50 and 850. Whilst I accept that
DWI is not necessary for the interpretation of breast
MRI scans, there are occasions when it can be very help-
ful, provided the series is of acceptable quality. In the
presence of a known cancer and florid BPE, working out
exactly what is malignant and what is not can be very
difficult and it is here that the DWI can be helpful [26]
(Fig. 4). However, if you are trying to evaluate a 7 mm
mass or non-mass enhancement in a fatty breast, and
the DWI slices are 4 mm thick with a 2 mm gap and
poor fat suppression, it is probably not going to yield
any useful information. It may be enough merely to ‘eye-
ball’ the ADC map to establish whether there is restric-
tion of diffusion, but I generally copy and paste a ROI
from the high b value image to the ADC map. A catch
to be aware of is that certain high grade tumours, par-
ticularly triple negative basal phenotype cancers, com-
monly have areas of necrosis and may therefore have
high whole-lesion ADC values [27]. Use of a small ROI
may be more discriminatory (Fig. 5). On the other hand,
Fig. 3 The effect of motion on subtracted images. a Axial post-contrast subtracted image showing severe misregistration secondary to motion in
the left breast. It is not possible to identify nor gauge the extent of the known high grade DCIS in this patient. b Axial high resolution
fat suppressed T1 weighted image post contrast. The non-mass segmental enhancement in the left breast is identifiable (arrows). At pathology
there was 40 mm of high grade DCIS
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proteinaceous cysts may exhibit increased signal at high
b values, a low ADC and only intermediate T2 signal. In
instances like this a quick glance at the DCE series en-
ables the correct diagnosis (Fig. 6). It is also important
to be aware of the presence of any marker clips or sta-
ples, where susceptibility artefacts preclude useful ADC
measurements.
The next step is kinetic and morphological analysis of
any enhancement using the BI-RADS lexicon. In the
latest edition, published in 2013 [28], the descriptors
have been simplified and aligned with those in the
mammography and ultrasound sections. It is possible to
download a free pdf from the ACR BI-RADS website
that summarises the MRI lexicon and I recommend hav-
ing this to hand when reporting if you are not used to
the descriptors. The main changes in the lexicon are
summarised in Table 2. Descriptors that were infre-
quently used (such as central enhancement and enhan-
cing internal septations) have been removed. Non-mass
like enhancement becomes non-mass enhancement and
the terms ‘reticular/dendritic’ and ‘stippled’ used to de-
scribe it have also been removed, as they were used
Fig. 4 Multifocal carcinoma in a patient with florid BPE (same patient as in Additional file 1: Figure S4b). First (a) and second (b) post-contrast
subtractions showing diminished tumour to background contrast in the second acquisition. c Delayed high resolution fat suppressed T1W
image showing tumour at 12 o’clock (solid arrow) and florid BPE especially at four o’clock (dashed arrow). Note similar signal intensities in the
two areas. Axial T2W (d) and corresponding ADC map (e) show subtle T2 hyperintense tumour and obvious restriction of diffusion in the mass.
Note similarity of distribution of restricted diffusion to enhancing tumour in (a). Extent of tumour for treatment planning is well depicted in
the sagittal reconstruction of the first post-contrast subtraction (f)
Fig. 5 ADC measurement in a grade 3 triple negative breast cancer with some central necrosis. a b850 image (b) whole tumour ADC (c) ‘hot
spot’ or ADCmin which is substantially lower
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infrequently and stippled enhancement is recognised as
a normal type of BPE. One addition is the term ‘clus-
tered ring’ to describe a form of non-mass enhancement
often associated with DCIS, as shown in Fig. 7.
When evaluating mass or non-mass enhancement I
prefer to link the relevant series, as shown in Fig. 8, so
that multiparametric assessment of any finding is facili-
tated. After I have made a morphological assessment
using the BI-RADS descriptors, kinetic assessment fol-
lows. All of the major MRI manufacturers have their
own analysis packages which produce colour overlays on
the dynamic series; generally speaking a lesion that is
bright red is one that is enhancing rapidly, above a cer-
tain percentage threshold. These overlays are useful in
drawing one’s attention to areas of enhancement where
time-intensity curves should be drawn. I tend to move a
small region of interest around looking for the ‘worst’
curve; that is, rapid enhancement with washout (type 3
curves). Often washout can be easily appreciated from
the MIP series, but of course if there is any motion dur-
ing the dynamic series (a frequent occurrence) it will not
be possible to generate meaningful time-intensity curves
Fig. 6 Cystic benign change. Axial b850 image (a), corresponding ADC map (b), T2 weighted image (c) and post-contrast T1 weighted image
demonstrating restriction of diffusion in a proteinaceous cyst (d). There is an ovoid lesion with high b850 signal (a) and restricted diffusion (arrowed)
(b). There is intermediate signal within it on T2W imaging (c) but the high resolution post-contrast sequence shows a small amount of enhancement
around a cyst, with other cysts elsewhere (d)
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unless there is very good motion correction (Fig. 3). It is
for this reason that I always evaluate the raw data as well
as the subtracted series. On the other hand, without the
subtracted series, high T1 signal in the ducts could be
wrongly interpreted as segmental enhancement rather
than the presence of proteinaceous fluid as occurs with
duct ectasia.
As a general principle it is most helpful to look at the
early post-contrast subtractions to differentiate between
malignancy and florid BPE (Fig. 4). During later acquisi-
tions, there may be very little tumour-to-background
contrast because of washout from the malignancy and
persistent enhancement of BPE. Often, unsuspected foci
of ipsilateral malignancy tend to have the same enhance-
ment characteristics as the index lesion – though beware
instances of two different immunophenotypes within the
same breast (Fig. 9).
Certain key measurements need to be documented in
the report. Not only should the size of a lesion be given
(in three planes), but also the quadrant, clock face pos-
ition and distance from the nipple. Generation of ‘route
maps’ in the appropriate plane are helpful, not only for
the surgeon but also for the unfortunate radiologist or
sonographer who may have to do a second-look targeted
ultrasound. If there are small satellite lesions within a
few mm of a known cancer I tend to include these in
the overall dimensions, but if the MRI demonstrates
further lesions that were not expected, it is essential
to document their location and their relationship with
the index lesion; again, reformatted route maps are
very useful.
Before I finish reviewing a study I have a mental
checklist of review areas. The axilla of a cancer–bearing
breast must be examined carefully and if there is obvi-
ously a heavy nodal burden the axillary apex and supra-
clavicular fossa should be reviewed. It is easy to miss
enlarged lymph nodes in the internal mammary chain,
Table 2 A summary of key changes in the BI-RADS MRI lexicon
Feature 2013 BI-RADS Atlas
Breast composition a (fatty)through to d (extreme FGT)
BPE level Minimal, mild, moderate, marked
BPE distribution Symmetric or asymmetric
Focus Removed from BPE section
Mass shape ‘lobular’ removed: oval, round or irregular
only
Mass margin ‘smooth’ removed: circumscribed, irregular
or spiculated only
Mass internal enhancement ‘Enhancing internal septations’ and ‘central
enhancement’ removed
Non-mass enhancement
(nme)
Non-mass like removed
Nme distribution ‘ductal’ removed
Nme internal enhancement
characteristics
‘Stippled/punctate’ removed (a normal
pattern of BPE)
‘reticular/dendritic’ removed
‘clustered ring’ added
Intramammary lymph node New addition as separate feature
Skin lesion New addition as separate feature
Associated findings Skin invasion: new descriptors (‘direct
invasion’, ‘inflammatory cancer’)
Oedema: removed
‘Lymphadenopathy’: removed. Now
termed ‘axillary adenopathy’
‘Chest wall invasion’ added; separate
from pectoral muscle invasion
‘Nipple retraction’ removed
Non-enhancing findings Ductal precontrast high signal on
T1W added
Cyst added
Postoperative collections (haematoma/
seroma) added
Post therapy skin/trabecular thickening
added
Architectural distortion added
Fat containing lesions New section (includes fat necrosis,
lymph nodes, hamartomas etc.)
Kinetic curve assessment New section: initial phase (slow,
medium, fast), delayed phase
(persistent, plateau, washout)
Implants New section: includes material and
type, location, evidence of rupture,
abnormal implant contour, signs of
intracapsular rupture; extracapsular
silicone (breast or lymph nodes),
water droplets or peri-implant fluid
Fig. 7 Clustered ring enhancement in a patient with extensive DCIS
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Fig. 8 Multiparametric breast MRI. From top left to bottom right: DWI (b850), ADC map, T2W image and T1W post-contrast subtracted image.
There is an obvious carcinoma in the upper outer quadrant of the right breast. An unexpected second rounded enhancing mass deep in the right
breast is slightly hyperintense on the T2 weighted image (arrow) and has high signal on the b850 image, but there is no restriction of diffusion.
Notice also a non-enhancing internal septation (dashed arrow). Biopsy-proven fibroadenoma
Fig. 9 Patient with known grade 1 classical invasive lobular carcinoma in the upper inner quadrant of the right breast. MRI was indicated as the
patient had breast implants and the breasts were difficult to assess with conventional imaging. Unexpected finding of a second carcinoma in
the upper outer quadrant. a Post contrast subtracted image, (b) high resolution delayed post contrast image, (c) regions of interest and (d)
time-intensity curves. Note different morphology and kinetics of the two lesions; lesion 3 in the lateral breast was a hormone receptor positive
grade 3 invasive ductal carcinoma
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an important observation as it may affect radiotherapy
planning. Satisfaction of search is important; whereas it
is hard to overlook an enhancing lesion in the contralateral
breast, it is very easy to overlook small bone metastases,
liver lesions or lung nodules. All of these are commoner
with a large primary tumour (T3 or 4) and N2 nodal dis-
ease and there is a particularly high incidence with inflam-
matory breast cancer, a condition that is readily apparent
with breast MRI.
Assigning a BI-RADS category
In MRI, BI-RADS 1 and 2 lesions have no probability of
malignancy. It is a question of preference whether to
mention entities such as cysts, old scars or obvious
fibroadenomas; if you do, you are bound to call these
BI-RADS 2. I try always to minimise the number of cat-
egory 3 (probably benign) lesions as these are a bit of an
unknown quantity in breast MRI. Though in some retro-
spective series, with variable follow-up and histopatho-
logical correlation, the rate of malignancy is low (around
2 %) [29, 30], in other series it is around 4 % [31]. The
presence of a T2 correlate, any restriction of diffusion
and the size of the lesion can be helpful. There is evi-
dence that the rate of BI-RADS 3 categorisation de-
creases with experience and with maturation of a
screening programme; ideally the rate should be well
under 10 % and preferably nearer 3 %. BI-RADS 4 le-
sions have a probability of malignancy of between 5–
95 % and thus constitute a bit of a dumping ground; but
importantly, these lesions should not be left alone. It is
here that correlation with non-contrast MRI and con-
ventional imaging can be really helpful. For example, if a
small mass has features of a lymph node, the presence of
washout does not matter; this is a category 2 lesion. Fat
necrosis can appear highly suspicious, with spiculate
masses and washout kinetics, but the diagnosis should
be apparent from evaluation not only of the non-
contrast images but also conventional imaging.
In considering categorisation, morphology and kinetics
should be considered together, but morphology is the
most important feature. Certain carcinomas may have
type 1 curves (especially classical ILC), but the morph-
ology is usually highly suspicious. Kinetic analysis may
not be possible at all with linear non-mass enhancement
as seen with DCIS, especially if there has been any
movement. Conversely, some myxoid fibroadenomata
may have washout curves; here the T2 correlate and
DWI signal is very useful. The morphological feature
with highest PPV for malignancy is spiculation, followed
by irregular shape or margin, and heterogeneous or rim
enhancement [32–34]. Clumped nodular and clustered
ring enhancement are the features of non-mass enhance-
ment with the highest PPV for malignancy [31, 35]. On
the other hand, round or oval, smooth non-enhancing
masses or masses with non-enhancing internal septa-
tions are virtually never malignant. Finally, BI-RADS 5
lesions have a greater than 95 % chance of malignancy.
In the US, a known biopsy proven carcinoma is category
6, though this category tends not to be used in the UK. I
can think of only a handful of occasions when I strug-
gled to assign this category to a known invasive carcin-
oma; two were mucinous carcinomas, and the rest were
very small screen-detected ILC that barely enhanced at
all. On the other hand, though some authors report an
exceptionally high sensitivity of MRI for DCIS, espe-
cially high grade [10], it is not uncommon to miss
intermediate and low grade DCIS especially if the scans
are poor quality.
It is important to remember that even in the pres-
ence of a known malignancy, multiple small enhancing
foci are nearly always benign [31] and I try not to over-
call these. Otherwise there is the risk of overstaging,
especially with invasive lobular carcinoma. Patients
undergoing local staging will usually have had image
guided biopsy, which can results in peritumoural
stranding, and (usually) mild enhancement – this
should not be mistaken for the presence of an associ-
ated extensive DCIS.
The report and management recommendations
As emphasised in the excellent introductory overview on
how to read cancer imaging studies by Professor Hicks,
probably the single most important factor in the issuing
of a helpful report is a thorough understanding of the
precise clinical question and of the factors that will in-
fluence the treatment plan. Above all, keep a sense of
perspective – when a patient has a grade 3, triple nega-
tive breast cancer that is shown on MRI to be locally
advanced (T4) with obvious extensive nodal involve-
ment, the presence of a small focus of non-mass
enhancement that is indeterminate (BI-RADS MRI 3) in
the contralateral breast is to all intents and purposes
irrelevant. The same is true of a similar focus in a differ-
ent quadrant of the same breast since it is highly likely
that the patient will ultimately require mastectomy. On
the other hand, the decision to go for mastectomy
should not be made on the basis of a second lesion with-
out histological confirmation.
By and large, a BIRADS MRI 3 mass less than 5 mm
or a focal non-mass enhancement under 10 mm does
not need further evaluation [36]. Thus, recommending a
second look ultrasound or even MRI-guided biopsy may
not be necessary, though in the US this would generally
mandate short interval (6 month) follow-up. It helps to
think about what you will do if you cannot find the
lesion on ultrasound; is there sufficient concern that
MRI guided biopsy would then be considered? If so, it
should probably be a category 4 lesion.
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For BI-RADS 3 lesions that are larger than 5 mm
(masses) or 10 mm (nme) I would generally perform
second look ultrasound if it will influence manage-
ment. Reassuringly, the incidence of malignancy in le-
sions without a second look ultrasound correlate is
relatively low (though variable) [37, 38], but attention
to scan technique is critical. For BI-RADS 4 lesions,
further evaluation is always indicated. With second
look ultrasound, careful attention must be paid to al-
tered spatial relationships. The sonographic correlates
of the MRI lesion are often very subtle [39] and if
anything is seen that might correspond to the lesion,
it should be biopsied and a marker clip inserted. I
have found two techniques to be helpful in this re-
gard; firstly, the use of shear wave elastography to
help identify subtle lesions and secondly, the use of
ultrasound guided vacuum assisted biopsy. This is
particularly helpful in cases of segmental nme, where
the location of the abnormality is known. This will
often result in definitive histology. Failing that, MRI
guided biopsy is necessary and this should be done in
a timely fashion so that there are no delays in the
patient pathway.
For cases of known cancer staging, I give a T stage
where possible. However, it is worth remembering that
surgical management of a cancer depends not only on
the absolute size of the lesion in relation to the size of
the breast, but also on the site of the abnormality. A
3 cm lesion can often be treated by wide local excision if
it is situated in the upper outer quadrant of a large
breast; but this will not be the case if the lesion lies in
the upper inner quadrant. Similarly, the orientation of
the malignancy has a significant impact on the treatment
options. A lesion that is oriented radially towards the
nipple can often be resected even if it is over 5 cm
in length (Fig. 10); whereas if the maximal diameter
is in the coronal plane, breast conservation will rarely
be possible even with oncoplastic techniques. Finally,
Fig. 10 Two different patients with DCIS. a, b There is segmental clumped nodular enhancement over at least 6 cm at 12 o’clock, extending to
the nipple. c There is segmental linear non mass enhancement at two o’clock in the right upper inner quadrant over 4.5 cm. Breast conservation
was possible in the first case but not in the second
Vinnicombe Cancer Imaging  (2016) 16:17 Page 11 of 14
if the patient obviously has more than four lymph
nodes that are involved by metastatic disease, I will
recommend whole body staging if this has not already
been carried out.
There are instances where I pursue indeterminate
findings much more aggressively; namely in the case of
women with BRCA mutations undergoing screening
MRI, especially if there is a known or suspected BRCA 1
mutation. BRCA 1 cancers tend to grow extremely rap-
idly and have a distinct phenotype; they often appear be-
nign, being rounded and relatively well defined [40].
Washout kinetics need not be present when they are
small and they can look remarkably like fibroadenomas.
This is one instance in which I may pursue masses
under 5 mm in size, as these tumours have a very fast
doubling rate. If no lesion is found on second look ultra-
sound I would then advise either very short interval
follow-up or MR guided biopsy. The management ap-
proach I use is summarised in Table 3.
Conclusions
Breast MRI is a remarkably powerful tool but if we are
to do no harm, the onus is on us to appreciate the lim-
itations of the technique and to issue a clear and con-
cise report that details the level of concern and the
actions, if any, that need to be taken. I am a great be-
liever in brevity when it comes to reports; I want my
reports to be read! Therefore I tend not to exhaust-
ively list all the scan parameters and all the normal/
benign findings. If resources permit double-reporting,
this is highly desirable especially when a service is
being introduced. Indeed, in the UK it is a quality re-
quirement for high risk family history scans, which are
carried out under aegis of the NHS breast screening
programme. Failing that, adoption of a standardised
approach to reporting, such as the one I have dis-
cussed above, minimises the likelihood of errors or
omissions. In summary:
 Have a thorough understanding of the strengths and
weaknesses of breast MRI
 Have a good indication and choose your patients
carefully
 Ensure the patient is well prepared
 Understand the precise clinical question and the
findings that will alter treatment
 Use recognised descriptors in your report
 Describe precisely where lesions are in relation to
landmarks such as the nipple; give a T stage
 Check all nodal stations carefully including apical
and internal mammary lymph nodes
 Remember satisfaction of search; check the other
breast!
 Check for extramammary findings (lungs, bone
visualised liver)
 Give a concise report with a final assessment score
and a clear management recommendation
Additional file
Additional file 1: Figure S4. Background parenchymal enhancement. a
Axial post contrast subtracted image; minimal BPE in the right breast and
a large enhancing cancer in the left upper inner quadrant (same patient
as in Fig. 2). b Axial MIP series post intravenous contrast in a patient with
known right breast cancer, for staging MRI. Severe BPE. c MIP image in a
patient who has previously had radiotherapy to the right breast. Note
absence of BPE in the right breast compared to the left. (ZIP 4210 kb)
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Table 3 A summary of management recommendations
Cases for second look ultrasound
Normal mammogram
Indeterminate or suspicious masses >5 mm
Areas of focal nme >10 mm
Recommend what should be done if no ultrasound correlate can
be identified
Cases for MRI guided biopsy
Normal mammogram and second look ultrasound
Indeterminate or suspicious masses >5 mm
Areas of focal nme >10 mm
Cases for follow-up MRI (screening)
Suspicious mass <5 mm or nme <10 mm: follow up at 6/12
(BRCA 1) or 12/12
Inconclusive biopsy: follow up at 6/12
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